登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
ClinicalTrials.gov 上登记的一项肺癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07778940,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Radiological and/or cerebrospinal fluid (CSF) cytological evidence of leptomeningeal metastases (LM). The diagnosis of non-small cell lung cancer (NSCLC) must be confirmed by histological and/or cytological examination.
入选标准第 4 条
Patients who have received prior brain and/or spinal cord radiotherapy, including stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT), are eligible, provided that radiotherapy was completed at least 7 days prior to the initiation of study treatment.
入选标准第 12 条
Concurrent intrathecal therapy with other agents is prohibited. For patients who have received other systemic therapies, the minimum washout periods are as follows: patients who have received prior intrathecal therapy must complete the last treatment at least 7 days before initiating study treatment; patients who have received systemic chemotherapy must complete the last treatment at least 14 days before initiating study treatment; patients who have received approved systemic immunotherapy (e.g., anti-PD-1, anti-CTLA-4) must complete the last treatment at least 14 days before initiating study treatment; patients who have received any other investigational drugs must complete the last treatment at least 14 days before initiating study treatment.
入选标准第 13 条
ECOG performance status of 0 to 2, with no deterioration within the past 7 days.
入选标准第 3 条
Patients must meet at least one of the following criteria: failure of first- or second-generation TKI therapy with T790M mutation negative; failure of third-generation TKI therapy; or EGFR mutation negative with failure of first-line therapy.
入选标准第 5 条
Male or female of non-childbearing potential, or female of childbearing potential who is not pregnant or lactating.
入选标准第 2 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07778940,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age between 18 and 75 years. Male or female of non-childbearing potential, or female of childbearing potential who is not pregnant or lactating. ECOG performance status of 0 to 2, with no deterioration within the past 7 days. Radiological and/or cerebrospinal fluid (CSF) cytological evidence of leptomeningeal metastases (LM). The diagnosis of non-small cell lung cancer (NSCLC) must be confirmed by histological and/or cytological examination. Patients must meet at least one of the following criteria: failure of first- or second-generation TKI therapy with T790M mutation negative; failure of third-generation TKI therapy; or EGFR mutation negative with failure of first-line therapy. If concurrent brain parenchymal metastases are present, they must have received appropriate treatment or been evaluated as stable over the past three months. Additionally, extracranial lesions must be evaluated as stable under the current treatment regimen. Adequate organ and bone marrow function, as evidenced by the following laboratory parameters: HGB ≥ 90 g/L; NEUT ≥ 1.5 × 10⁹/L; PLT ≥ 80 × 10⁹/L; TBIL ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN (if liver metastases are present, ALT and AST ≤ 5 × ULN); creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula); urine protein < (++) or 24-hour urine protein < 1.0 g; normal coagulation function without active bleeding; INR ≤ 1.5; APTT ≤ 1.5 × ULN. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment and must voluntarily use adequate contraception during the study period and for 8 weeks after the last dose of the study drug. Males must be surgically sterilized or agree to use adequate contraception during the study period and for 8 weeks after the last dose of the study drug. Prior Ommaya reservoir implantation. Estimated life expectancy of ≥ 12 weeks. No history of severe neurological diseases or severe hematological abnormalities. Patients who have received prior brain and/or spinal cord radiotherapy, including stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT), are eligible, provided that radiotherapy was completed at least 7 days prior to the initiation of study treatment. Concurrent intrathecal therapy with other agents is prohibited. For patients who have received other systemic therapies, the minimum washout periods are as follows: patients who have received prior intrathecal therapy must complete the last treatment at least 7 days before initiating study treatment; patients who have received systemic chemotherapy must complete the last treatment at least 14 days before initiating study treatment; patients who have received approved systemic immunotherapy (e.g., anti-PD-1, anti-CTLA-4) must complete the last treatment at least 14 days before initiating study treatment; patients who have received any other investigational drugs must complete the last treatment at least 14 days before initiating study treatment. Ability to provide written informed consent, including compliance with the requirements and restrictions listed in the informed consent form. Patients must have good compliance, voluntarily agree to participate in the clinical study, sign the informed consent form, and be willing to cooperate with follow-up visits.排除标准:Exclusion Criteria:
Patients requiring ventriculoperitoneal (VP) shunt placement due to elevated intracranial pressure. History of epilepsy unrelated to leptomeningeal metastases. Evidence of any neurological functional failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy as shown on imaging, or a Glasgow Coma Scale (GCS) score < 11. Evidence of any extensive and fatal progressive systemic disease with no effective treatment available. Prior allogeneic bone marrow transplantation or solid organ transplantation. Uncontrolled hypertension prior to enrollment, defined as: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg. Surgical procedures involving vital organs within 3 months prior to enrollment. Any disease or condition prior to enrollment that affects drug absorption. Clinically significant cardiovascular diseases, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months prior to enrollment; congestive heart failure with New York Heart Association (NYHA) classification > Grade 2; ventricular arrhythmias requiring medication; left ventricular ejection fraction (LVEF) < 50%; or other related diseases such as severe pulmonary, hepatic, or renal dysfunction, severe gastrointestinal ulcers, or coagulation dysfunction. Active or uncontrolled severe infections (≥ Grade 2 infections per CTCAE v5.0). Known human immunodeficiency virus (HIV) infection. Known history of clinically significant liver disease, including viral hepatitis [Known hepatitis B virus (HBV) carriers must be excluded if they have active HBV infection, defined as HBV DNA positive (>1×10⁴ copies/mL or >2000 IU/mL); known hepatitis C virus (HCV) infection with HCV RNA positive (>1×10³ copies/mL)]. Any other disease, clinically significant metabolic abnormalities, physical examination abnormalities, or laboratory abnormalities that, in the investigator's judgment, provide reason to suspect a disease or condition that makes the patient unsuitable for the study drug (e.g., seizures requiring treatment), will affect the interpretation of study results, or place the patient at high risk. Patients with a prior history of basal cell or squamous cell skin cancer, cervical carcinoma in situ, or other cancers may be considered for enrollment if there is evidence of being disease-free for more than 5 years after treatment. Severe neurological or psychiatric history; active disseminated intravascular coagulation (DIC); or other concomitant diseases that, in the investigator's judgment, seriously jeopardize patient safety or affect the patient's ability to complete the study. Participation in other clinical trials, receipt of investigational drugs, or any concomitant treatments containing investigational drugs within 14 days prior to enrollment. Patients deemed unsuitable for this study by the investigator.
引自 ClinicalTrials.gov, NCT07778940, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07778940,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。